RxDoctor Payments Data

Liezelle Jurgens, MD

Internal Medicine · Chattanooga, TNNPI 1285619866

Payments from drug & device makers

$5,929in general payments, 2019–2025

Across 353 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$990
  • AbbVie$767
  • Lilly USA, LLC$543
  • AstraZeneca$518
  • Pfizer$512
  • Astellas Pharma US Inc$296
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,83598%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,929 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$114,785
Medicare patients
328
Services billed
3,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$78,641
MounjaroTirzepatide68$74,559
OzempicSemaglutide48$54,466
TrulicityDulaglutide23$28,166
XareltoRivaroxaban15$22,689
JardianceEmpagliflozin20$16,896
MyrbetriqMirabegron35$16,299
Tresiba Flextouch U-100Insulin Degludec16$13,611
EntrestoSacubitril/Valsartan12$13,009
Bydureon BciseExenatide Microspheres13$11,267
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,117
Breo ElliptaFluticasone/Vilanterol20$7,864
Atorvastatin Calcium409$5,959
Valsartan116$5,197
Levothyroxine Sodium543$4,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$543$102,72691 claims
PfizerEliquis$512$78,64189 claims
Novo NordiskOzempic$990$54,46648 claims
Johnson & JohnsonXarelto$55$22,68915 claims
Boehringer IngelheimJardiance$53$16,89620 claims
Astellas Pharma US IncMyrbetriq$296$16,29935 claims
GSKTrelegy Ellipta, Breo Ellipta$195$15,98131 claims
NovartisEntresto$33$13,00912 claims
AbbVieSynthroid$767$2,62157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →